Rachel Pearce
Director of Business Development @SK pharmteco
Signup · Get unlimited contacts
WORK HISTORY
Director of Business Development @SK pharmteco
Oxfordshire, GB
SK pharmteco brings over 80 years of experience to manufacturing small molecule drug substances for some of the world\'s leading therapeutics including cardiology and oncology drugs.We assist with process development, optimisation and scale-up with a focus on operational excellence and continuous improvement towards commercial cGMP manufacturing of intermediates and APIs from gram to MT. Our global development and manufacturing footprint include facilities in Ireland, across the US and in South Korea. All of our facilities offer the highest assurance of quality and compliance as demonstrated by a strong record of EHS performance with 29 successful audits since 2020 (by global regulatory agencies including the FDA, EMA, PMDA and ANVISA) and production of 39 approved products across our sites.SK pharmteco is a leading CDMO partner with over m³ capacity and offers an unique combination of manufacturing technologies and modalities- Energetic Chemistry - Continuous Flow Processing, including hydrogenation at all scales- SMB and Batch chromatography- Very high containment (OEL down to 10 nanogram/m³) for ADC payloads- Controlled Substances (US DEA Schedule II-V Manufacturing)- Particle Engineering (micronization and spray-drying)- Oligonucleotides and Peptides
EDUCATION
University of Oxford
MChem, Chemistry
ABOUT RACHEL PEARCE
I work with pharma and biopharma teams at the point where development chemistry stops being “good enough” and has to survive the realities of pivotal trials, filing, and commercial supply.Most of the situations I’m involved in are not greenfield. They’re inherited: • a process that worked at small scale but is now under strain • an in-licensed asset with an existing CDMO relationship • chemistry that becomes high-risk once potency, energy, or particle control really matterI’m a trained medicinal chemist, but my role today sits in the grey space between technical confidence and commercial consequence. I help teams quickly determine whether their current manufacturing strategy is genuinely fit for the next phase — or whether it’s quietly accumulating risk.At SK Pharmteco, I support small-molecule API programs where standard approaches fall short, particularly involving highly potent, energetic, continuous, or particle-engineered chemistry. We’re not the right partner for every program — and recognising that early is usually the most valuable part of the conversation.If you’re approaching a transition point and want a clear-eyed view on whether your current setup will hold, I’m always open to comparing notes.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.